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Loss of TACI Causes Fatal Lymphoproliferation
and Autoimmunity, Establishing TACI
as an Inhibitory BLyS Receptor
(Gross et al., 2000; Marsters et al., 2000; Shu and John-
son, 2000; Thompson et al., 2000; Wu et al., 2000; Yan
et al., 2000a; Yu et al., 2000). BR3 and TACI are also
expressed on resting and activated CD4 T cells, re-
spectively (Yan et al., 2001a). BR3 binds BLyS exclu-
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sively, while BCMA and TACI also bind to APRIL (Mars-Genentech, Inc.
ters et al., 2000; Yu et al., 2000). All three receptors for1 DNA Way
BLyS lack an intracellular death domain, suggesting aSouth San Francisco, California 94080
role for BLyS primarily in cell survival and/or differentia-
tion. While an essential function for BLyS in B cell devel-
opment has been established, distinct roles for each ofSummary
the three receptors in BLyS signaling have not been
clearly defined to date. BCMA/ mice have no dis-BLyS, a key cytokine that sustains B cell maturation
cernable phenotype indicating a redundant, or as yetand tolerance, binds three receptors: BR3, BCMA, and
undiscovered, role for BCMA (Xu and Lam, 2001). OnTACI. Results from knockout mice implicate a major
the other hand, a natural strain of mice, A/WySnJ, ex-functional role for BR3 and a redundant one for BCMA
pressing a mutant nonfunctional BR3 (Yan et al., 2001a)in B cell function. TACI’s role is controversial based
exhibit a block in B cell development with a severeon defects in TI antibody responses accompanied by
decrease in the number of peripheral B cells. In addition,B cell hyperplasia in knockout mice. We have presently
B cells with mutated BR3 receptor from A/WySnJ micecharacterized a precise role for TACI in vivo. TACI/
are unable to respond to soluble BLyS demonstratingmice develop fatal autoimmune glomerulonephritis,
a critical role for BR3 in B cell activity (Thompson et al.,proteinurea, and elevated levels of circulating autoan-
2001; Yan et al., 2001a). Initial reports on TACI/ micetibodies. Treatment of B cells with TACI agonistic anti-
have revealed conflicting roles for TACI in BLyS signal-bodies inhibits proliferation in vitro and activation of
ing. von Bulow et al. (2001) observed normal splenica chimeric receptor containing the TACI intracellular
architecture, B cell maturation, and T-dependent hu-domain induces apoptosis. These results demonstrate
moral responses but a greatly decreased T-independentthe critical requirement for TACI in regulating B cell
response (von Bulow et al., 2001). These results sug-homeostasis.
gested a positive role for TACI in T-independent anti-
body production. In contrast, Yan et al. (2001b) observedIntroduction
increased B cell accumulation in vivo. In addition,
TACI/ B cells hyperproliferated and produced in-BLyS (B lymphocyte stimulator, also called BAFF,
creased immunoglobulins in vitro. These conflicting re-TALL-1, and THANK) is a member of the TNF ligand
sults have complicated the interpretation of TACI’s rolesuperfamily and is known to be a critical molecule for
in BLyS signaling.B cell survival, maturation, and tolerance (Groom et al.,
The finding that cytoplasmic tails of BR3 and TACI are2002; Gross et al., 2001; Khare et al., 2000; Moore et
neither conserved nor possess a recognizable signalingal., 1999). BLyS is expressed primarily on dendritic cells
motif such as a death domain or a consensus TRAFand monocytes/macrophages and can be cleaved into
binding sequence (Yan et al., 2001a), and that BLySa soluble form by furin-type proteases like other mem-
binds to both of these receptors with equivalent affinity,
bers of the TNF superfamily (Moore et al., 1999; Schnei-
adds additional complexity to this system. The similarity
der et al., 1999). BLyS is most closely related in
in phenotype of mice lacking BLyS and functional BR3,
sequence to APRIL, another member of the TNF super- coupled to the finding that B cells with mutated BR3
family. BlyS/mice do not have mature B cells, resulting receptor do not respond to soluble BLyS, suggests that
in low circulating Ig levels and decreased antibody- BLyS stimulates B cells primarily through BR3. Claudio
mediated immune responses (Gross et al., 2001; Schie- et al. (2002) and our studies by Kayagaki et al. (2002)
mann et al., 2001). In contrast, BLyS transgenic mice have shown that binding of BLyS to BR3 promotes pro-
have increased numbers of B cells and develop autoim- cessing of NF-B2/p100 resulting in a survival signal
mune diseases such as systemic lupus erythematosus that is critical for maintenance of peripheral B cells.
(SLE) and Sjogren’s syndrome (SS), indicating an impor- Thus, while the physiological roles of BR3 as a crucial
tant role for BLyS-mediated signals in the development receptor for BLyS in B cell survival are clear, the relative
and long-term survival of autoreactive B cells (Gross et role of TACI is not fully understood at present.
al., 2000; Khare et al., 2000; Mackay et al., 1999). To determine the in vivo role for TACI, we have fully
BLyS has been shown to bind to three receptors, characterized the phenotype of TACI/ mice in the
BCMA (B cell maturation antigen), BR3 (BLyS receptor present study. These mice develop lymphoproliferation
3, also called BAFF-R), and TACI (transmembrane acti- and massive multi-organ infiltration of lymphocytes in
vator and calcium modulator and cyclophilin ligand the liver and kidney. Loss of TACI also results in develop-
[CAML] interactor), all of which are expressed on B cells ment of fatal lupus-like autoimmune disease as evi-
denced by proteinurea and circulating -dsDNA and
-nuclear autoantibodies, suggesting a dominant inhibi-*Correspondence: iqbal@gene.com
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Figure 1. Lymphadenopathy, Splenomegaly,
and Development of Lymphoma in TACI/
Mice
Enlarged spleens and lymph nodes from
TACI/ mice (A and C) and wild-type control
littermates (B and D) are shown. Histology of
lymphoma in the spleen of TACI/ mice is
shown in (E) and (G). Metastasis of this lym-
phoma to the liver is shown in (F) and (H). (E)
and (F) are under low magnification and (G)
and (H) are under high magnification. 15%
of TACI/ mice developed lymphoma at 7
months of age. 20 mice from age-matched
groups of wild-type and knockouts were ana-
lyzed (p  0.0465).
tory role for TACI in maintaining B cell homeostasis. an average 2- to 3-fold increase in the numbers of B
cells in the spleen and lymph nodes (data not shown).This was confirmed in vitro using both TACI agonistic
antibodies and a chimeric receptor comprising the intra- Histology of enlarged spleens from TACI/ mice dem-
cellular domain of TACI. Addition of antibody and spe- onstrated expansion of the red pulp areas, and that of
cific activation of the chimeric receptor through soluble enlarged lymph nodes demonstrated normal follicular
EDA.A1 ligand inhibited B cell proliferation in a dose- architecture with expansion in all areas of the cortical
dependent manner. This inhibition of B cell proliferation follicles and interfollicular T cell regions (data not
may be due to the induction of apoptosis by the TACI shown). This histology is characteristic of a lymphopro-
intracellular domain. Thus, the dramatic phenotype of liferative disorder. TACI/ mice also exhibited lympho-
TACI/ mice coupled with the in vitro studies of TACI cyte infiltration in various organs including liver and kid-
activation demonstrates the in vivo importance of nega- ney (data not shown). Interestingly, TACI/ mice
tive regulation of B lymphocyte activity by TACI. developed low frequency lymphoma/leukemia in the
spleen that metastasized to the liver (Figures 1E–1H).
Results 15% of TACI/ mice developed the lymphomas at 7–8
months of age as compared to none of the control wild-
type or heterozygotes, observed up to 18 months ofLymphoproliferation and Multi-Organ Infiltration
in TACI/ Mice age. 20 mice from age-matched groups of wild-type and
knockouts were analyzed. In panels (E) and (G), the whiteTo determine the role of TACI in BlyS-mediated effects
in vivo, we studied mice lacking TACI. TACI/ mice pulp in the spleen was diffusely infiltrated and ablated
by a dense sheet of neoplastic round cells with palehave enlarged spleen and lymph nodes, as shown in
Figures 1A–1D. This increase in size is accompanied by basophilic cytosol, indistinct cell borders, and oval,
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Figure 2. TACI/ Mice Develop SLE-like Au-
toimmune Disease
Kidney sections from 7-month-old TACI/
and wild-type littermates stained with hae-
matoxylin and eosin show amyloid deposition
and thickened mesangium of the glomeruli in
the TACI/ mice (A) and absent in the wild-
type controls (B). Deposition of IgG in renal
glomeruli was detected by direct immunoflu-
orescence using frozen kidney sections from
7-month-old TACI/ and wild-type lit-
termates (C–F). IgG deposition in the kidney
is shown in TACI/ mice (C and E) and no
such deposition was seen in wild-type con-
trols (D and F). (C) and (D) are under low mag-
nification and (E) and (F) are under high mag-
nification. Ten TACI/ and ten wild-type
animals were evaluated.
open-faced nuclei and a high mitotic index (10–15 per angial proliferation and inflammatory cell infiltrates (Fig-
ures 2A–2B). Fibrinoid necrosis and sclerosis werehigh-power field). The liver was similarly infiltrated with
massive numbers of malignant lymphocytes. The he- prominent in affected glomeruli accompanied by occa-
sional crescent formation. Immunofluorescence stain-patic sinusoids contained a similar population of neo-
plastic round cells that formed coalescing masses that ing of the kidney revealed IgG deposits (Figures 2C–2F).
The TACI/ mice had significant deposition of IgG inimpinged upon and disrupted hepatic cords. Intravascu-
lar neoplastic round cells (lymphoma) were also present renal glomeruli as determined by direct immunofluores-
cence. Nine out of ten animals evaluated had high levelsin most tissues evaluated. Immunohistochemistry with
-B220 antibody identified numerous strong staining of diffuse staining of glomeruli. TACI/ mice had focal
to diffuse global moderate membranoproliferative glo-B220 cells in the liver. These lymphomas were most
likely B cell lymphomas due to their staining with B220. merulonephritis characterized by mesangial prolifera-
tion, inflammatory cell infiltration, and subendothelialThese data suggest that in the absence of TACI, lympho-
cytes undergo deregulated proliferation leading to deposits. These changes and immunoglobulin deposits
were absent in age-matched wild-type control animals.,multiorgan tissue damage and lymphoma development.
suggesting that loss of TACI in vivo results in develop-
ment of glomerulonephritis.TACI/ Mice Show Histological Signs
of Glomerulonephritis
To determine if lymphoproliferation shown in Figure 1 TACI/ Mice Develop Autoimmune Disease
with SLE-like Symptomsresulted in autoimmune disease, we analyzed TACI/
mice for symptoms of systemic lupus erythematosus The histological identification of autoimmune glomerulo-
nephritis in TACI/ mice suggested that renal function(SLE). TACI/ mice succumbed to diffuse membrano-
proliferative glomerulonephritis characterized by mes- might be impaired in these mice. Renal damage was
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Figure 3. TACI/ Mice Develop Fatal Lupus-Associated Pro-
teinurea and Autoantibodies
(A) 7-month-old TACI/ mice and wild-type littermate controls were
tested for proteinurea and values are shown in (A). All 10 wild-type
mice had proteinurea levels under 30 mg/dl, while seven out of eight
TACI/ mice displayed levels over 300 mg/dl. Figure 4. TACI/ Mice Display Normal Levels of Circulating BLyS
(B) Levels of circulating -dsDNA autoantibodies in the serum of and Do Not Express a Truncated TACI Protein
7-month-old TACI/ mice and wild-type littermate controls were (A) Serum levels of BLyS were analyzed in n  3 TACI wild-type
assayed by ELISA. OD 450 values are shown in the figure. and knockout mice by Western blotting and were not elevated in
(C) Titers of -nuclear antibodies in TACI/ and wild-type lit- TACI/ mice.
termates were analyzed using an ANA kit and OD 450 values are (B) Levels of TACI protein were assayed by FACS (upper panel) and
shown. Western blotting (lower panel) using an antibody that recognizes
(D) Mortality statistics for TACI wild-type and knockout mice are the N-terminal extracellular domain of TACI. Splenocytes from n 
graphed in (D) (p  0.0052). 5 TACI wild-type and knockout littermates were gated for B220 and
analyzed for TACI expression (isotype control in gray, wild-type in
red, and knockout in green). Protein lysates from purified CD19
splenic B cells were also analyzed by Western blotting. Expressionconfirmed by the presence of significant proteinurea in
of TACI was detected in wild-type but not knockout mice. EqualTACI/mice (Figure 3A). Levels of proteinurea gradually
loading was confirmed by probing for -actin.
increased in TACI/ mice, and by 7 months of age,
while none of the wild-type littermates displayed levels
of proteinurea greater than 30 mg/dl, 100% of TACI/ indicate the important requirement for TACI-mediated
signals to control autoimmune diseases such as lupushad levels greater than 100 mg/dl and90% had levels
over 300 mg/dl. Proteinurea was observed in both male mediated primarily by B cells.
Since BLyS transgenic mice also develop lupus (Grossand female knockout mice with equal frequency. Other
hallmarks of lupus, such as circulating dsDNA and anti- et al., 2000; Khare et al., 2000; Mackay et al., 1999), it
is possible that the observed phenotype in TACI micenuclear autoantibodies, were also detected at high lev-
els in TACI/ mice while being absent in age-matched is due to an indirect effect of increased circulating levels
of BLyS resulting from lack of TACI. To rule out thiswild-type control littermates (Figures 3B–3C). Lympho-
proliferation and autoimmune disease resulted in de- possibility, we assayed levels of BLyS in the serum of
wild-type and TACI/ mice by Western blotting (Figurecreased survival of TACI knockouts when compared to
wild-type littermates (Figure 3D). 12 out of 32 knockout 4A) and ELISA (data not shown). Levels of BLyS were
comparable in both wild-type and knockout mice, con-mice (40%) died by 18 months of age, while 100% of
wild-types and heterozygotes survived. These results firming that the observed phenotype of autoimmunity
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results from a loss of TACI signaling and is not an indirect the TACI intracellular domain. Toward this goal, we mo-
lecularly engineered a chimeric receptor composed ofeffect of increased available BLyS. The targeting strat-
egy for generating TACI knockout mice involved the the mouse TACI trans membrane and intracellular do-
mains fused to an EDAR extracellular domain (Figuredeletion of its trans-membrane and intracellular do-
mains. This brings up the possibility that autoimmune 6A). EDAR is the receptor for a TNF superfamily ligand,
EDA.A1, and is not expressed in the immune systemdisease may result from a dominant-negative effect on
the other BLyS receptors, BR3 and BCMA, by a trun- (Yan et al., 2000b). A mouse B cell line A20 (Shimonkevitz
et al., 1983) was stably transfected with this chimericcated protein comprising only the extracellular domain
of TACI. Toward this end, levels of TACI were assayed receptor and expression was confirmed through FACS
analyses of FLAG-tagged soluble EDA.A1 ligand bindingby both FACS and Western blotting using an antibody
that recognizes the N-terminal extracellular domain of (Figure 6B). No binding of EDA ligand was detected to
control mock-transfected A20 cells (left panel), whileTACI (Figure 4B). Splenocytes from five wild-type and
TACI knockout littermates were gated for B220 and ana- specific binding of the -FLAG antibody was observed
to two different clones of A20.EDAR/TACI cells (middlelyzed for TACI expression (upper panel). FACS analyses
revealed the absence of any detectable truncated pro- and right panels). Control A20 cells (Figure 6C) and a
clone expressing high levels of the chimeric receptortein in TACI/ B cells. Purified CD19 B cells were also
isolated from spleens and analyzed by Western blotting (Figure 6D) were then stimulated with LPS or a combina-
tion of-CD40 antibody/IL4. When the chimeric receptor(lower panel). Expression of TACI was detected in wild-
type but not knockout mice. Equal loading was con- was activated in the presence of EDA ligand, an average
of 2- to 3-fold inhibition was observed in proliferation,firmed by probing for -actin. The complete absence of
a truncated TACI protein in TACI/ mice may be due indicating that activation of the TACI intracellular do-
main could repress LPS- or -CD40 antibody-inducedto improper folding of the mutant protein, resulting in
its inability to reach the cell surface. The above results, proliferation. Thus, the above results from both in vitro
approaches in human and mouse B cells systems clearlyhowever, indicate that the observed phenotype is not
due to a dominant-negative effect of a truncated TACI reinforce the inhibitory nature of TACI-mediated signals
during B cell activation.protein.
TACI Intracellular Domain Can InduceActivation of TACI Intracellular Domain Inhibits
Apoptosis in Mouse A20 CellsB Cell Proliferation In Vitro
The ability of the chimeric receptor to suppress bothA 2-fold in vitro approach was also adopted to confirm
LPS- and -CD40 antibody-induced proliferation maythe inhibitory role for TACI in B cell signaling in vivo.
result from its ability to induce apoptosis in these cells.First, agonistic antibodies to TACI were generated and
To examine this possibility, survival assays usingeffects of these antibodies on signaling in human pri-
annexin-FITC were performed using control mock-mary B cells were studied. Figure 5A demonstrates bind-
transfected A20 (Figure 7A) and two separate clones ofing of the three monoclonal antibodies, 6D11, 7B6, and
A20.EDAR/TACI cells (Figures 7B–7C). Control A20 cells4C7, used in the study to 293 cells transfected with full-
in the presence of EDA.A1 ligand and stimulated withlength human TACI. No binding of the TACI antibodies
LPS or -CD40 antibody/IL4 did not undergo apoptosis.to mock-transfected 293 cells was observed (data not
However, activation of the TACI intracellular domain byshown). In Figure 5B, the agonistic activity of two of the
EDA.A1 in A20 cells expressing the chimeric receptorthree antibodies (6D11 and 7B6) is shown, as evidenced
induced apoptosis and reduced survival by 30%–40%.by the activation of an NFB-luciferase reporter in 293
This induction was detected at comparable levels bothcells (Yan et al., 2000a). 6D11 and 7B6 were able to
in the presence and absence of activation signals suchactivate the NF-B reporter when compared to soluble
as LPS or -CD40 antibody/IL4, suggesting that thehuman BLyS, which was used as a control. The third
TACI intracellular domain is able to actively induce apo-antibody 4C7 did not stimulate reporter activity and is
ptosis in these cells. Mechanisms of inhibition other thannot an agonistic antibody. The 6D11 antibody blocked
apoptosis by TACI in B cells are also being investigated.binding of BLyS to TACI; however, 7B6 and 4C7 did not
(ELISA, data not shown). As shown in Figure 5C, -CD40
antibody-induced B cell proliferation was inhibited in a Discussion
dose-dependent manner by the two agonistic mono-
clonal antibodies to TACI. All three antibodies are the The in vivo role of TACI in the regulation of B cell activa-
tion is presently highly controversial and is further com-same mouse isotype (IgG1), and 4C7 served as a
matched isotype control antibody. The level of back- plicated by its ability to bind another TNF superfamily
ligand, APRIL (Gross et al., 2000; Marsters et al., 2000).ground B cell proliferation in the absence of any stimulus
was subtracted from each of the indicated values in the While APRIL/ mice have not been characterized to
date, data from APRIL transgenic mice (Stein et al., 2002)graph. The observation that both 6D11 and 7B6 could
stimulate NF-B activity in 293 cells and inhibit B cell rule out a dominant role for this ligand in B cell activation.
These results and the published data (Gross et al., 2000;proliferation, while the nonagonistic antibody 4C7 could
do neither, indicates that the observed effects on prolif- Khare et al., 2000; Schiemann et al., 2001) strongly impli-
cate BLyS as the sole ligand for TACI in the regulationeration are due to an active inhibitory signal induced by
TACI. of B cell function. Defining a precise physiological role
for TACI in vivo has been complicated by conflictingSecond, we adopted a chimeric receptor approach
to study potential inhibitory signals mediated through reports from several labs. Studies by von Bulow et al.
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Figure 5. TACI Agonistic Antibodies Inhibit B
Cell Proliferation
(A) Three monoclonal antibodies generated
in mouse to human TACI (6D11, 7B6, and 4C7)
bind to 293 cells transfected with 0.1 g full-
length human TACI for 24 hr and analyzed by
FACS using a PE-conjugated -mouse IgG1
secondary antibody. Isotype control is shown
in gray.
(B) Human 293 cells were transfected with 0.1
g of a full-length human TACI expression
plasmid along with 1 g of ELAM-luciferase
reporter plasmid and 0.1 g control pRL-TK
plasmid. After 4 hr, indicated amounts of sol-
uble recombinant human BLyS or TACI anti-
bodies were added for 20 hr and reporter
gene activity determined. Two out of three
antibodies (6D11 and 7B6) display agonistic
activity as evidenced by activation of the
NFB-luciferase reporter. Variations in trans-
fection efficiencies were controlled for by us-
ing equal amounts of protein and an internal
Renilla reporter control.
(C) 5  105 human B cells isolated from pe-
ripheral blood by positive selection using
magnetic beads were stimulated with-CD40
antibody (10 g/ml) and IL-4 (100 ng/ml) and
increasing concentrations of two different
clones of TACI agonistic antibodies for 72 hr.
[H3] counts are plotted as a function of TACI
agonistic antibody concentration. All three
antibodies are the same mouse isotype (IgG1)
and 4C7 served as a matched isotype control
antibody. The level of background B cell pro-
liferation in the absence of any stimulus has
been subtracted from each of the indicated
values in the graph. The two TACI agonistic
antibodies 6D11 and 7B6 significantly inhibit
B cell proliferation induced by -CD40 anti-
body/IL4, while the nonagonistic antibody
4C7 does not.
(2001) using TACI/ mice suggested an important posi- ties of TACI observed in vivo, thus supporting its physio-
logical roles.tive role for TACI in thymus-independent and a re-
dundant role in thymus-dependent B cell responses. The mechanisms by which TACI may mediate BLyS-
induced inhibitory signals are presently unclear. ResultsInterestingly, they also observed increased splenic ac-
cumulation of B cells, but these cells matured normally. from BLyS transgenic and knockout mice strongly sug-
gest that the crucial requirement for BLyS in B cell devel-Yan et al. (2001b)’s reports using TACI/ mice have
added more complexity to this issue. In this report, B opment may be due to its ability to inhibit apoptosis
and promote survival. Furthermore, our recently re-cells lacking TACI were observed to be hyperresponsive
in vitro. Thus, delineating the exact nature of TACI’s ported studies by Kayagaki et al. (2002) indicate that
BR3 may be the sole BLyS receptor mediating thesecontribution to B and T cell function has not been per-
formed to date. Previous studies have established an antiapoptotic effects through its ability to activate the
NF-B2 survival pathway. One possible method byessential role for BLyS in B cell stimulation mediated
primarily through BR3 (Kayagaki et al., 2002; Yan et al., which TACI is mediating its inhibitory function may be
due to its ability to sequester BLyS and prevent its bind-2001a). Our studies presented here represent conclusive
evidence that unlike BR3, TACI is an inhibitory receptor, ing to BR3, thus inhibiting B cell survival. In this context,
it is of interest to discuss interactions between BR3 andwhich regulates B cell functions in vivo. Our results re-
veal that loss of TACI results in lymphoproliferation, lym- TACI signaling when B cells expressing both receptors
encounter BLyS in vivo. Resting B cells express higherphoma development, and severe autoimmune nephritis
with autoantibody production, leading to death of the levels of BR3 transcripts than BCMA or TACI (D.S. and
I.S.G., unpublished data) and this may serve to delivermice. Furthermore, our in vitro studies using agonistic
anti-TACI antibodies and molecular approaches utilizing a constant survival signal. Interestingly, upon activation
with BLyS/-IgM, TACI transcripts are selectively upreg-a chimeric TACI receptor confirm the inhibitory proper-
TACI Is an Inhibitory BLyS Receptor in B Cells
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Figure 6. EDAR/TACI Chimeric Receptor
Signals Inhibit Proliferation of Mouse A20
Cells
(A) Design of the EDAR/TACI chimeric recep-
tor is shown. The fusion protein was con-
structed by fusing the extracellular domain of
human EDAR (residues 1–183) and the trans-
membrane and intracellular domains of mu-
rine TACI (residues 130–249).
(B) Two different clones of murine A20 cells
electroporated with pCIneo-EDAR/TACI were
analyzed for FLAG-tagged EDA.A1 ligand
binding using a FITC-conjugated -FLAG an-
tibody. Binding of ligand to control A20 cells
and two different clones of A20.EDAR/TACI
cells is shown. Isotype control is shown in
red and binding of -FLAG antibody in green.
(C and D) 5  105 control mock-transfected
A20 (C) and A20.EDAR/TACI.c5 cells (D) were
stimulated with LPS (0.5 mg/ml) or -mouse
CD40 antibody (5 g/ml) and IL-4 (100 ng/
ml) in the presence or absence of indicated
amounts of soluble recombinant human
EDA.A1 protein. Addition of soluble EDA li-
gand significantly inhibited LPS- and -CD40
antibody-induced proliferation in A20 cells
expressing the chimeric receptor, while hav-
ing no effect on control A20 cells.
ulated to levels higher than BR3, suggesting that BLyS receptor in mouse A20 cells. Activation of the TACI intra-
cellular domain induced apoptosis and reduced survivalmay selectively be able to signal through TACI upon B
cell activation due to TACI receptor upregulation. TACI by 40%–50% as assayed by annexin-FITC staining.
Studies of potential mechanisms of action of TACI-may thus play an inhibitory role and serve to terminate
responses in the later stages of B cell activation. This induced apoptosis are complicated by the absence of a
canonical death domain in the TACI intracellular domainis reminiscent of roles for CD28 and CTLA-4 in regulating
T cell responses (Gross et al., 1992; Linsley et al., 1996) (Marsters et al., 2000; Yan et al., 2000a). However, TNF
receptors such as the LT- receptor and TNF-RII haveand will be further studied upon the availability of anti-
bodies to track cell surface expression of BR3, TACI, been shown to activate apoptosis upon ligand binding
despite the absence of a death domain (Browning et al.,and BCMA. Hence, TACI may function as an inhibitory
receptor by out-competing BR3 for binding to BLyS or 1996; Force et al., 2000; Li et al., 2002). These mecha-
nisms involve association with ubiquitin ligases suchby directly antagonizing BR3-mediated signaling. These
mechanisms may not be mutually exclusive and need as c-IAP1, leading to ubiquitination and proteasomal
degradation of survival molecules (Li et al., 2002), theto be investigated in future studies. At this stage, how-
ever, the former possibility cannot fully account for its activation of TRAF molecules such as TRAF 1, 2, 3, and
5 (Nakano et al., 1996; Rothe et al., 1995, 1994), andobserved inhibitory function in vivo based on the compa-
rable levels of serum BLyS in wild-type and TACI/ prolonged activation of the JNK pathway (Wallach et
al., 1999). Intriguingly, TACI activation by BLyS in a Bmice and results from our studies using TACI agonistic
antibodies and an EDAR-TACI chimeric receptor, which cell line has been shown to result in JNK activation (Xia
et al., 2000), and in this context it is of interest to mentionindicate that activation of the intracellular domain of
TACI can inhibit B cell activation. that TACI has been shown to associate with TRAFs 2,
5, and 6 (Xia et al., 2000), and this TRAF associationThe observed phenotype of lymphoproliferation and
autoimmunity in TACI/ mice suggests that TACI may may lead to the observed activation of NF-B by TACI
(Marsters et al., 2000). This paradoxical ability of TACIbe able to promote apoptosis in activated B cells, and
this was observed in our studies with the TACI chimeric to induce both survival and apoptotic pathways is similar
Immunity
286
to accumulate elevated levels of the proapoptotic gene
blk (bik-like killer), which may be one potential reason
for the decreased survival of these B cells (Amanna et
al., 2001). It is not yet known if this deregulated expres-
sion of blk is due to a lack of BR3 signaling or deregu-
lated TACI signaling by BLyS. Further studies are
needed to identify downstream adaptor molecules that
can induce apoptosis in B cells through TACI signaling.
It is also possible that TACI is inhibiting B cell activation
through mechanisms other than apoptosis and these
are currently being investigated.
The mechanisms by which a multiple ligand-receptor
system (BLyS-BR3/TACI/BCMA) can maintain homeo-
stasis and regulate B cell function in vivo have hitherto
been a puzzle. In this respect, our data provide the
following strong evidence for a mechanism by which
the same ligand is able to induce both positive and
negative signals by binding to alternate receptors. First,
our studies demonstrate the ability of a single ligand,
BLyS, to act as both an activator and inhibitor of B cells,
which represent a system in which this has not been
shown before. An analogous system exists for T cells,
where CD80/CD86-CD28/CTLA-4 ligand-receptor inter-
actions operate to regulate function (Sharpe and Free-
man, 2002). As in the T cell system, where CD28 func-
tions as a costimulatory receptor while CTLA-4 provides
an inhibitory signal upon engagement by their ligands,
activation of the two receptors (BR3 and TACI) by BLyS
could also result in opposing effects on B cell function.
Second, considering the dominant role played by BR3
in B cell responses (Schneider et al., 2001; Thompson
et al., 2001; Yan et al., 2001a), no definitive role for TACI
in B cell activity has been demonstrated previously. In
this respect, our studies clearly establish an essential
role for BLyS-TACI interactions in regulation of B cell
function in vivo. Third, our studies also demonstrate a
crucial role for TACI in keeping the immune system in
check by regulating lymphoproliferation and preventing
spontaneous autoimmunity. The severe phenotype of
TACI/ mice accompanied by results from our in vitro
studies demonstrates the critical requirement for TACI-
mediated negative regulation of lymphocyte function
and strongly supports a model for the dual regulation of
B cells by BLyS, in which signals through TACI receptor
inhibit B cell activity and signals through BR3 lead to
stimulation of B cell survival.
While our studies clearly demonstrate a negative role
Figure 7. Activation of the TACI Intracellular Domain Induces Apo- for TACI in B cell homeostasis, its role in T cell function
ptosis in A20 Cells Expressing a Chimeric Receptor
is still unclear. TACI has been shown to be expressed
2  105 control A20 (A), A20.EDAR/TACI.c5 (B), and A20.EDAR/ on T cells and studies by Huard et al. (2001) indicate a
TACI.c7 (C) were stimulated with LPS (0.5 mg/ml) or -mouse CD40
positive role for BLyS signaling in T cells. They demon-antibody (5 g /ml) and IL-4 (100 ng/ml) in the presence or absence
strated the ability of BLyS to induce T cell proliferationof soluble recombinant human EDA.A1 protein (5 g /ml). Cells were
and cytokine secretion when combined with -TCRstained with annexin-FITC/PI at 0 and 48 hr postactivation to assay
survival. Activation of the chimeric receptor by addition of soluble stimulation. This result raises an intriguing question
EDA ligand induced apoptosis in A20 cells expressing the chimeric about the identity of the receptor mediating these ef-
receptor, while having no effect on control A20 cells. fects. BCMA expression has not been detected on T
cells to date, suggesting that it may not contribute to
the observed BLyS effects on T cells. In a previous report
to that observed for TNF-RII (Pimentel-Muinos and from our lab, analyses of BR3 and TACI transcript levels
Seed, 1999). The activation of these dual pathways may revealed a differential pattern of expression in T cells
be context dependent and also provide a possible expla- (Yan et al., 2001a). BR3 was predominantly expressed
nation for the diminished TI responses in TACI/ mice. on resting cells while TACI was upregulated upon activa-
Interestingly, B cells from A/WySnJ mice expressing a tion. The ability of T cells from TACI/ mice to respond
to BLyS (D.S. and I.S.G., unpublished data) indicatesmutant nonfunctional BR3 protein have been reported
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ences). Clones of A20 cells expressing the EDAR/TACI chimericthat BR3 may be the major positive receptor. Interest-
receptor were analyzed for FLAG-tagged EDA.A1 binding using aingly, when compared to wild-type cells, TACI/ T cells
FITC-conjugated -FLAG M2 antibody (Sigma-Aldrich).were observed to hyperproliferate when stimulated with
-CD3 antibody and BLyS. The results strongly suggest Proliferation and Survival Assays
an inhibitory role for TACI in T cell function. However, Human B cells were isolated from blood from donors using Lympho-
the possibility that TACI may be playing a positive role cyte Separation Medium (ICN Pharmaceuticals) followed by purifica-
tion using CD19 MACS beads (Miltenyi Biotech). 5  105 cellsin T cell function cannot be ruled out and studies are
were induced to proliferate using a combination of -human CD40currently underway to resolve this issue.
antibody (10 g/ml) (BD Pharmingen) and IL-4 (100 ng/ml) (R&D
Systems) for 72 hr. Mouse A20 cells were stimulated with LPS (0.5Experimental Procedures
mg/ml) (Sigma-Aldrich) or -mouse CD40 antibody (5 g/ml) and
IL-4 (100 ng/ml) (R&D Systems), in the presence or absence ofCell Culture and Transfections
soluble recombinant human EDA.A1 protein for 72 hr. Cells wereThe EDAR/TACI chimeric protein was constructed by fusing to-
pulsed with 1 Ci [H3]-dT for the last 6 hr of culture and harvested.gether PCR fragments of the extracellular domain of human EDAR
For survival assays, 2  105 cells were incubated with LPS (0.5 mg/(residues 1–183) and the transmembrane and intracellular domains
ml) or -mouse CD40 antibody (5 g/ml) and IL-4 (100 ng/ml), inof murine TACI (residues 130–249). The construct was confirmed
the presence or absence of soluble recombinant human EDA.A1by sequencing in a pGEMT vector (Promega Corporation) and
protein (5 g/ml). At the indicated time points, cells in the respectivecloned into pCIneo expression vector (Promega Corporation). Mu-
cultures were stained with Annexin V-FITC/PI (Clontech Labs) andrine A20 cells maintained in RPMI 1640, 10% FBS, and L-glutamine
analyzed by FACS.were electroporated with 20 g of pCIneo or pCIneo-EDAR/TACI
plasmid. Cells were selected in 1 mg/ml G418 for 2 weeks and
NF-B Reporter Assaysclones isolated by limiting dilution.
Human 293 cells were transfected with 0.1 g of a full-length human
TACI expression plasmid along with 1 g of ELAM-luciferase re-
Antibody ELISAs and Proteinurea
porter plasmid and 0.1g control pRL-TK plasmid (Promega Corpo-
Levels of circulating dsDNA antibodies in serum were analyzed by
ration). After 4 hr, indicated amounts of soluble recombinant human
ELISA using plates coated with poly dA-dT/polyL-Lysine (Sigma-
BLyS or TACI antibodies were added for 20 hr and reporter gene
Aldrich) and HRP-conjugated anti-mouse IgG1 antibody (Caltag
activity was determined using a dual-luciferase reporter assay sys-
Laboratories). Titers of -nuclear antibodies were detected by using
tem (Promega Corporation).
ANA screen kit (Sigma-Aldrich, St. Louis, MO) and HRP-conjugated
-mouse IgG antibody (Caltag Laboratories). The presence of pro-
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